Centiva Capital’s BioXcel Therapeutics BTAI Stock Holding History

Centiva Capital’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,338	Closed	-$47.9K	–	2164
2024 Q2	$47.9K	Buy	+2,338	New	+$78.3K	﹤0.01%	1929

Other funds holding BTAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Centiva Capital's BTAI Position: Q3 2024 in Review

Centiva Capital sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 2,338 shares — an estimated $47.9K sold.

Centiva Capital first reported a position in BTAI in Q2 2024 and held it in 1 quarter. The position peaked at $47.9K in Q2 2024. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

Centiva Capital reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 2,338 BioXcel Therapeutics shares in Q3 2024, an estimated $47.9K.
Centiva Capital first reported a position in BioXcel Therapeutics in Q2 2024 and held it in 1 quarter.
Centiva Capital's BioXcel Therapeutics position peaked at $47.9K in Q2 2024.
49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.